期刊
NEUROPSYCHOPHARMACOLOGY
卷 31, 期 8, 页码 1745-1749出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.npp.1300992
关键词
selective serotonin reuptake inhibitor; SSRI; positron emission tomography; PET; [11C]WAY-100635
资金
- NIMH NIH HHS [MH62185, MH40695] Funding Source: Medline
Serotonin 1A (5-HTIA) binding potential (BP) as assessed by positron emission tomography (PET) is higher in major depressive disorder (MDD) in association with the higher expressing GG genotype of the 5-HT1A C-1019G polymorphism. We hypothesize that higher 5-HT1A BP and the GG genotype predict remission failure on antidepressant treatment. We determined 5-HT1A BP by PET and 5-HT1A C-1019G genotype in 43 controls and 22 medication-free MDD subjects. MDD was treated naturalistically and remission was defined as > 50% reduction and a score of <= 10 on the 24 item Hamilton Scale I year after initiation of treatment after scanning. Despite equivalent treatment, nonremitters have higher pretreatment cortical BP and the GG genotype is over-represented compared with remitters. Higher 5-HT1A BP, perhaps due to greater gene expression, may predict antidepressant medication nonremission. The findings should be tested in a controlled prospective treatment study.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据